Role of hypermutability on bacterial fitness and emergence of resistance in experimental osteomyelitis due to Staphylococcus aureus

FEMS Immunology and Medical Microbiology

Volumn 51, Issue 2, 2007, Pages 344-349

  Daurel, Claire ^c,d   Prunier, Anne Laure ^b,c   Chau, Françoise ^c   Garry, Louis ^e   Leclercq, Roland ^d   Fantin, Bruno ^a,c  

^a BEAUJON HOSPITAL   (France)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d CHU CÔTE DE NACRE   (France)

^e INSERM   (France)

Author keywords

Experimental infections; Rifampicin; Staphylococcus aureus

Indexed keywords

CIPROFLOXACIN; FUSIDIC ACID; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BONE INFECTION; CONTROLLED STUDY; DISEASE MODEL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MUTL GENE; NONHUMAN; OSTEOMYELITIS; PHENOTYPE; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS AUREUS;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BACTERIAL PROTEINS; BONE AND BONES; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, BACTERIAL; GENE DELETION; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, INSERTIONAL; OSTEOMYELITIS; RATS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS;

EID: 35148867407     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00310.x     Document Type: Article

References (24)

1. Aubry-Damon H, Soussy CJ Courvalin P (1998) Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 42 : 2590 2594.
2. Besier S, Ludwig A, Brade V Wichelhaus TA (2005) Compensatory adaptation to the loss of biological fitness associated with acquisition of fusidic acid resistance in Staphylococcus aureus. Antimicrob Agents Chemother 49 : 1426 1431.
3. Bjorkman J, Nagaev I, Berg OG, Hughes D Andersson DI (2000) Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287 : 1479 1482.
4. Blondeau JM, Zhao X, Hansen G Drlica K (2001) Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45 : 433 438.
5. Comité de l'Antibiogramme de la Société Française de Microbiologie. Communiqué 2006. (15 October 2006 date last accessed).
6. Denamur E, Bonacorsi S, Giraud A et al 2002) High frequency of mutator strains among human uropathogenic Escherichia coli isolates. J Bacteriol 184 : 605 609.
7. Denamur E, Tenaillon O, Deschamps C, Skurnik D, Ronco E, Gaillard JL, Picard B, Branger C Matic I (2005) Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli. Genetics 171 : 825 827.
8. LeClerc JE, Li B, Payne WL Cebula TA (1996) High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 274 : 1208 1211.
9. Lew DP Waldvogel FA (1997) Osteomyelitis. N Engl J Med 336 : 999 1007.
10. Marti TM, Kunz C Fleck O (2002) DNA mismatch repair and mutation avoidance pathways. J Cell Physiol 191 : 28 41.
11. Morosini MI, Baquero MR, Sanchez-Romero JM, Negri MC, Galan JC, del Campo R, Perez-Diaz JC Baquero F (2003) Frequency of mutation to rifampin resistance in Streptococcus pneumoniae clinical strains: hexA and hexB polymorphisms do not account for hypermutation. Antimicrob Agents Chemother 47 : 1464 1467.
12. Oliver A, Canton R, Campo P, Baquero F Blazquez J (2000) High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288 : 1251 1254.
13. O'Neill AJ Chopra I (2003) Lack of evidence for involvement of hypermutability in emergence of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 47 : 1484 1485 author reply 1485.
14. O'Reilly T Mader JT (1999) Rat model of bacterial osteomyelitis of the tibia. Handbook of Animal Models of Infection (Zak O Sande M, eds), pp. 561 575. Academic Press, San Diego, CA.
15. Picard B, Duriez P, Gouriou S, Matic I, Denamur E Taddei F (2001) Mutator natural Escherichia coli isolates have an unusual virulence phenotype. Infect Immun 69 : 9 14.
16. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M Peters G (2006) Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4 : 295 305.
17. Prunier AL Leclercq R (2005) Role of mutS and mutL genes in hypermutability and recombination in Staphylococcus aureus. J Bacteriol 187 : 3455 3464.
18. Prunier AL, Malbruny B, Laurans M, Brouard J, Duhamel JF Leclercq R (2003) High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 187 : 1709 1716.
19. Richardson AR, Yu Z, Popovic T Stojiljkovic I (2002) Mutator clones of Neisseria meningitidis in epidemic serogroup A disease. Proc Natl Acad Sci USA 99 : 6103 6107.
20. Schaaff F, Bierbaum G, Baumert N, Bartmann P Sahl HG (2003) Mutations are involved in emergence of aminoglycoside-induced small colony variants of Staphylococcus aureus. Int J Med Microbiol 293 : 427 435.
21. Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Kohrer K Milatovic D (1999) Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol Med Microbiol 26 : 281 287.
22. Taddei F, Radman M, Maynard-Smith J, Toupance B, Gouyon P H Godelle B (1997) Role of mutator alleles in adaptive evolution. Nature 387 : 700 702.
23. Trong HN, Prunier AL Leclercq R (2005) Hypermutable and fluoroquinolone-resistant clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 49 : 2098 2101.
24. Watson ME Jr., Burns JL Smith AL (2004) Hypermutable Haemophilus influenzae with mutations in mutS are found in cystic fibrosis sputum. Microbiology 150 : 2947 2958.